Abstracts tagged "pain and treatment"

Abstract Number: 295 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips
Jennifer Maloney¹, Alan Kivitz², Thomas J. Schnitzer³, Paula Dakin¹, Catherine Stehman-Breen¹ and Greg Geba¹, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Northwestern University, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is an important cause of chronic pain in older adults. Fasinumab is a fully-human, high-affinity monoclonal antibody directed against the nerve growth…
Abstract Number: 2302 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials
Lynne Pauer¹, Andrew Clair², Pritha Bhadra Brown², Marie Ortiz² and Joseph Scavone¹, ¹Pfizer Inc, Groton, CT, ²Pfizer Inc., New York, NY
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder for which Lyrica is an approved treatment. Antidepressants, gabapentin, muscle relaxants, and opioids are frequently used…
Abstract Number: 2407 • 2015 ACR/ARHP Annual Meeting
Comparison of Knee Osteoarthritis Treatment in the Non-Obese Versus Obese Populations Across Different Medical Specialties
Kelly Forrester¹, Farah Taufiq¹ and Jonathan Samuels^2,3, ¹NYU Langone Medical Center, New York, NY, ²Rheumatology, NYU - Hospital for Joint Diseases, New York, NY, ³Rheumatology, NYU Langone Medical Center, New York, NY
Background/Purpose: Knee osteoarthritis (KOA) in the obese population is underdiagnosed and routinely undertreated, as providers often attribute pain to excess weight without considering articular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].